ReviewLife (Basel, Switzerland)2024
Anti-Cryptosporidial Drug-Discovery Challenges and Existing Therapeutic Avenues: A "One-Health" Concern.
Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Unravelling the synergistic potential of Olibanum extract and Bacillus clausii in combating intestinal cryptosporidiosis in immunosuppressed mice.PLoS neglected tropical diseases · 2026Article
- Therapeutic Effects of Matricaria chamomilla Extract in an Immunosuppressed Mouse Model of Cryptosporidiosis.Veterinary medicine and science · 2026Article
- Antiparasitic Potential of Bioactive Compounds FromJournal of parasitology research · 2026Review
- Epidemiological Exploration ofVeterinary sciences · 2025Article
- Gut Barrier Dysfunction and Microbiota Variations in Cryptosporidiosis: A Comprehensive Review.Veterinary sciences · 2025Review
- Gastrointestinal Parasites With Their Risk Factors in Tharu Indigenous People in Southern Nepal: A Cross-Sectional Study.Health science reports · 2025Article
- Article
- Food and Waterborne Cryptosporidiosis from a One Health Perspective: A Comprehensive Review.Animals : an open access journal from MDPI · 2024Review
- Malate dehydrogenase in parasitic protozoans: roles in metabolism and potential therapeutic applications.Essays in biochemistry · 2024Review
- Cryptosporidium spp. prevalence in the general population in Guinea: first large-scale screening study.Parasite (Paris, France) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptosporidiosis is the leading cause of life-threatening diarrheal infection, especially in infants. Oocysts contaminate the environment, and also, being a zoonotic disease, cryptosporidiosis is a threat to One Health. Nitazoxanide is the only FDA-approved drug, effective only in immunocompetent adults, and is not safe for infants. The absence of mitochondria and apicoplast, the presence of an electron-dense band (ED band), hindrances in its genetic and phenotypic manipulations, and its unique position inside the host cell are some challenges to the anti-cryptosporidial drug-discovery process. However, many compounds, including herbal products, have shown efficacy against
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.